Director Cam Gallagher Buys $323K in Opus Genetics Stock, Signaling Confidence
Summary
Opus Genetics Director Cam Gallagher made a substantial open market purchase of $323,693 in company stock, signaling strong insider confidence.
Key Events
-
Director's Open Market Purchase
Director Cam Gallagher acquired 164,000 shares of Opus Genetics common stock through open market purchases totaling $323,693. The shares were bought at an average price between $1.97 and $1.98 on December 29, 2025.
-
Restricted Stock Unit Grant
Gallagher also received a grant of 33,000 restricted stock units (RSUs) on December 31, 2025, which are scheduled to vest on December 29, 2026, subject to continued service.
Analysis
Director Cam Gallagher's significant open market purchase of Opus Genetics stock, totaling over $323,000, indicates strong insider confidence in the company's prospects. This direct investment, alongside a restricted stock unit grant, suggests a positive outlook from a key board member. Investors may view this as a bullish signal, especially for a micro-cap company where insider buying can be particularly impactful.
At the time of this filing, IRD was trading at $2.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $138.6M. The 52-week trading range was $0.65 to $2.59. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.